May 2004 Table of Contents

External Link - article-94607.pdf

Articles in this issue

over 22 years ago

Article

The Risk Management Mandate

over 22 years ago

Article

Partners in Learning

over 22 years ago

Article

Early Warnings

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline

ByIvo Carre

August 24th 2026

Focusing on Asset Acquisition Over Building a Single Platform Technology

ByMike Hollan,Ying Huang, PhD

August 24th 2026

What the Peptide Advisory Vote Actually Means: Q&A with James LaValle

ByNicholas Jacobus,James LaValle

August 24th 2026

Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly

ByNicholas Jacobus

August 21st 2026

Your Questions Answered: What This Week's Rare Disease and Specialty Drug News Tells Us About Where the Industry Is Heading

August 21st 2026

May 2004 Table of Contents

Articles in this issue

Related Content

Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline

Focusing on Asset Acquisition Over Building a Single Platform Technology

What the Peptide Advisory Vote Actually Means: Q&A with James LaValle

Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly

Your Questions Answered: What This Week's Rare Disease and Specialty Drug News Tells Us About Where the Industry Is Heading

Trending on PharmExec

M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration

Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly

Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb

When Drug Pricing Becomes Trade Policy

FDA Approves Pasatru For Adults With Fibrodysplasia Ossificans Progressiva